Veradermics’ Hair Loss Drug Succeeds in Late-Stage Trial

Veradermics’ hair loss drug succeeds in late-stage trial

The company is one of the most advanced players in the hair loss field, which has seen a surge of investor enthusiasm.

Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Conference call will take place on Monday, April 27, 2026 at 8:00 am ET

Veradermics Stock Explodes 43% After Positive Phase 3 Hair Loss Drug Trial Results

NEW YORK — Veradermics Inc. shares skyrocketed more than 42% Monday, surging to $96.60 in morning trading after the dermatology-focused biopharmaceutical company announced strongly positive topline results from its Phase 2/3 clinical trial of VDPHL01, an oral treatment for male pattern hair loss that demonstrated early, consistent and robust hair growth.

Veradermics to discuss Monday results for oral hair-loss pill study

At 8 a.m. ET, Veradermics will review Part A data from its randomized, double-blind, placebo-controlled Phase 2/3 trial in male pattern hair loss.

Veradermics to Hold Conference Call to Discuss Topline Results from ...